Companies: 10,795·Total market cap: $144.5T
Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation

NYMXFOTCHealthcare● Active
$0.09
+$0.00(+0.00%)
Market Cap$8508613
P/E Ratio
52W High$0.1999
52W Low$0.03
Overview

Nymox Pharmaceutical Corporation (NYMXF) Revenue

Annual & quarterly revenue history · segment & region breakdown

NYMXF · revenue · updated Jun 10, 2026

Core revenue metrics

Nymox Pharmaceutical Corporation trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
16 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Nymox Pharmaceutical Corporation SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
NYMXF revenue by year · NYMXF revenue history · NYMXF annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Nymox Pharmaceutical Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Nymox Pharmaceutical Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Nymox Pharmaceutical Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

NYMXF revenue · 4 questions

NYMXF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

NYMXF revenueNYMXF annual revenuewhat is NYMXF revenueNYMXF TTM revenue

Source: FMP · Nymox Pharmaceutical Corporation SEC filings · GAAP · Nymox Pharmaceutical Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026